14625-39-9

Basic information

• Product Name: 2-(CHLOROMETHYL)-6-NITRO-1H-BENZO[D]IMIDAZOLE
• Synonyms: 2-(CHLOROMETHYL)-6-NITRO-1H-BENZO[D]IMIDAZOLE;2-Chloromethyl-6-nitro-1H-benzoimidazole;2-(chloroMethyl)-6-nitro-1HbenziMidazole;2-(Chloromethyl)-5-nitro-1H-benzimidazole;2-Chloromethyl-5-nitro-1H-benzoimidazole
• CAS NO: 14625-39-9
• Molecular Formula: C₈H₆ClN₃O₂
• Molecular Weight: 211.61
• Mol File: 14625-39-9.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 471.9°Cat760mmHg
• Flash Point: 239.2°C
• Appearance: /
• Density: 1.571g/cm³
• Vapor Pressure: 1.27E-08mmHg at 25°C
• Refractive Index: 1.715
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-(CHLOROMETHYL)-6-NITRO-1H-BENZO[D]IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)-6-NITRO-1H-BENZO[D]IMIDAZOLE(14625-39-9)
• EPA Substance Registry System: 2-(CHLOROMETHYL)-6-NITRO-1H-BENZO[D]IMIDAZOLE(14625-39-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 14625-39-9(Hazardous Substances Data)

Usage

General Description

2-(Chloromethyl)-6-Nitro-1H-benzo[d]imidazole is a chemical compound with the molecular formula C9H6ClN3O2. It is a derivative of benzo[d]imidazole, which is commonly used in the synthesis of pharmaceuticals and agrochemicals. The presence of a chloromethyl group and a nitro group in the compound makes it highly reactive and potentially useful as an intermediate in organic synthesis. It is also known for its antimicrobial and antiparasitic properties, and has been used in the development of drugs for the treatment of various infections. Additionally, it has shown potential as a pesticide and fungicide in agricultural applications.

InChI:InChI=1/C8H6ClN3O2/c9-4-8-10-6-2-1-5(12(13)14)3-7(6)11-8/h1-3H,4H2,(H,10,11)

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 20034-00-8 (5-nitro-1H-benzo[d]imidazol-2-yl)methanol 
• 79-11-8 chloroacetic acid 
• 97-02-9 2,4-Dinitroanilin 
• 6271-08-5 2-chloro-N-(2,4-dinitrophenyl)acetamide 
• 849435-69-4 N-(2-amino-4-nitro-phenyl)-2-chloro-acetamide 
• 36743-66-5 ethyl chloroacetimidate hydrochloride 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 1250259-03-0 5-nitro-2-[(styrylsulfonyl)methyl]-1H-benzimidazole 
• 1250259-06-3 5-nitro-2-[(4-methylstyrylsulfonyl)methyl]-1H-benzimidazole 
• 99876-66-1 5-nitro-2-(piperidin-1-ylmethyl)-1H-benzo[d]imidazole 

Relevant articles and documents

-

-

New 7-piperazinylquinolones containing (benzo[d]imidazol-2-yl)methyl moiety as potent antibacterial agents

A series of 7-piperazinylquinolones containing a (benzo[d]imidazol-2-yl)methyl moiety were designed and synthesized as new antibacterial agents. The antibacterial activity of title compounds was evaluated against Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis and Bacillus subtilis) and Gram-negative (Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumonia) microorganisms. Among the tested compounds, the N1-cyclopropyl derivative 4a showed the highest activity against S. aureus, S. epidermidis, B. subtilis and E. coli (MIC = 0.097 μ g/mL), being 2–4 times more potent than reference drug norfloxacin. A structure-activity relationship study demonstrated that the effect of the nitro group on the benzimidazole ring depends on the pattern of substitutions on the piperazinylquinolone.

Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects

To address drug resistance caused by ALK kinase mutations, a series of novel 2,4-diarylaminopyrimidine (DAAP) analogues were designed by incorporating 1H-benzo[d]imidazol motif onto the maternal framework. All compounds were efficiently synthesized and an

Design, synthesis, and evaluation of different scaffold derivatives against NS2B-NS3 protease of dengue virus

The number of deaths or critical health issues is a threat in the infection caused by Dengue virus, which complicates the situation, as only symptomatic treatment is the current solution. In this regard we have targeted the dengue protease NS2B-NS3 that is responsible for the replication. The series was designed with the help of molecular modeling approach using docking protocols. The series comprised of different scaffolds viz. cinnamic acid analogs (CA1–CA11), chalcone (C1–C10) and their molecular hybrids (Lik1–Lik10), analogs of benzimidazole (BZ1-BZ5), mercaptobenzimidazole (BS1-BS4), and phenylsulfanylmethylbenzimidazole (PS1-PS4). Virtual screening of various natural phytoconstituents was employed to determine the interactions of designed analogs with the residues of catalytic triad in the active site of NS2B-NS3. We have further synthesized the selected leads. The synthesized analogs were evaluated for the cytotoxicity and NS2B-NS3 protease inhibition activity and compared with known anti-dengue natural phytoconstituent quercetin as the standard. CA2, BZ1, and BS2 were found to be more potent and efficacious than the standard quercetin as evident from the protease inhibition assay.

Aromatic heterocycle-containing 2, 4-diarylaminopyrimidine derivative as well as preparation and application of 2, 4-diarylaminopyrimidine derivative

The invention relates to an aromatic heterocycle-containing 2, 4-diarylaminopyrimidine derivative represented by a general formula I, an optical isomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof, preparation methods of the aromatic heterocycle-containing 2, 4-diarylaminopyrimidine derivative and the optical isomer, the pharmaceutically acceptable salt, the solvate or the prodrug, and a pharmaceutical composition using the compound represented by the general formula I as an active component, wherein substituents R1, R2, R3, R4, R5, R6, X, Y and Z have meanings given inthe specification. The invention also relates to the compound shown in the general formula I, which has strong ALK and ROS1 kinase inhibition effects, and also relates to application of the compound and the optical isomer and pharmaceutically acceptable salt thereof in preparation of drugs for treatment and/or prevention of diseases caused by ALK and ROS1 abnormal expression, and application of the compound in preparation of drugs for prevention of diseases caused by ALK and ROS1 abnormal expression. Use in particular in the preparation of a medicament for treatment and/or for preventing cancer